# LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

> **NCT00466258** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 50 (estimated)

## Conditions studied

- HIV Infections
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** R-CHOP
- **DRUG:** Highly active antiretroviral therapy
- **DRUG:** Central nervous system (CNS) prophylaxis
- **DRUG:** Prophylaxis of opportunistic infections and support treatment

## Key facts

- **NCT ID:** NCT00466258
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-05
- **Final completion:** 2009-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00466258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00466258, "LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00466258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*